Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.

Abstract:

BACKGROUND:The epidemiology and pathophysiology of non-erosive gastro-oesophageal reflux disease differs from erosive gastro-oesophageal reflux disease. There is a possibility that non-erosive gastro-oesophageal reflux disease treatment requires a different regimen/approach but it is not yet acknowledged. AIM:To investigate the efficacy of famotidine and omeprazole in the treatment of gastro-oesophageal reflux disease, especially non-erosive gastro-oesophageal reflux disease. PATIENTS AND METHODS:A randomized, open-label trial was conducted. Fifty-four gastro-oesophageal reflux disease patients were assigned to treatment with famotidine at a dosage of 20 mg twice daily; or omeprazole, 20 mg once daily, for a period of 8 weeks. The Short Form-36 Health Survey and Gastrointestinal Symptom Rating Scale administered at baseline and after 8 weeks of treatment as well as a symptom questionnaire were conducted daily. RESULTS:Short Form-36 revealed that gastro-oesophageal reflux disease has severe impact on health-related quality of life. Thirty-nine subjects (77%) were endoscopically diagnosed as non-erosive gastro-oesophageal reflux disease. The mean Gastrointestinal Symptom Rating Scale abdominal pain, and indigestion score of non-erosive gastro-oesophageal reflux disease significantly improved in famotidine-treated patients (P < 0.05), but not in the omeprazole. There was no significant change regarding improved heartburn symptoms of non-erosive gastro-oesophageal reflux disease between treatments in the daytime or night-time. CONCLUSION:Famotidine and omeprazole were both effective in improving symptoms of gastro-oesophageal reflux disease, particularly non-erosive gastro-oesophageal reflux disease.

journal_name

Aliment Pharmacol Ther

authors

Wada T,Sasaki M,Kataoka H,Tanida S,Itoh K,Ogasawara N,Oshima T,Togawa S,Kubota E,Yamada T,Mori Y,Fujita F,Ohara H,Nakao H,Sobue S,Joh T,Itoh M

doi

10.1111/j.1365-2036.2005.02467.x

subject

Has Abstract

pub_date

2005-06-01 00:00:00

pages

2-9

eissn

0269-2813

issn

1365-2036

pii

APT2467

journal_volume

21 Suppl 2

pub_type

临床试验,杂志文章,随机对照试验
  • Systematic review: epidemiology of hepatitis C genotype 6 and its management.

    abstract:BACKGROUND:Hepatitis C virus (HCV) genotype 6 is common among patients from Southeast Asia and the surrounding regions, where HCV prevalence is also high. HCV genotype 6 has great genetic diversity and different response to antiviral therapy compared with the more commonly known genotype 1. AIM:Our goal was to provide...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2011.04714.x

    authors: Chao DT,Abe K,Nguyen MH

    更新日期:2011-08-01 00:00:00

  • Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans.

    abstract:BACKGROUND:The role of 5-hydroxytryptamine in the control of gastric fundus tone in humans is still unknown. Selective 5-hydroxytryptamine re-uptake inhibitors act both centrally and peripherally to enhance the availability of physiologically released 5-hydroxytryptamine. AIM:To study the influence of a selective 5-hy...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2003.01469.x

    authors: Tack J,Broekaert D,Coulie B,Fischler B,Janssens J

    更新日期:2003-02-15 00:00:00

  • Dose-response relationship of lansoprazole to gastric acid antisecretory effects.

    abstract:BACKGROUND:Proton pump inhibitors have been found to be effective in numerous studies in patients with peptic ulcer disease, particularly associated with Helicobacter pylori and gastro-oesophogeal reflux disorders. Optimal healing rates of antisecretory therapy for peptic acid disease is dependent upon the degree and d...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.1998.00306.x

    authors: Blum RA,Hunt RH,Kidd SL,Shi H,Jennings DE,Greski-Rose PA

    更新日期:1998-04-01 00:00:00

  • Occupational asbestos exposure and digestive cancers - a cohort study.

    abstract:BACKGROUND:Although the role of asbestos in the genesis of mesothelioma and primary bronchopulmonary cancers has been established, results from studies focusing on the relationship between occupational exposure to asbestos and digestive cancer remain contradictory. AIM:To determine whether occupational asbestos exposu...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2009.04050.x

    authors: Clin B,Morlais F,Dubois B,Guizard AV,Desoubeaux N,Marquignon MF,Raffaelli C,Paris C,Galateau-Salle F,Launoy G,Letourneux M

    更新日期:2009-08-15 00:00:00

  • Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.

    abstract:BACKGROUND:Symptoms of irritable bowel syndrome are often cyclical and thus may require repeated rather than continuous therapy. Tegaserod is effective and well-tolerated for irritable bowel syndrome with constipation but data on retreatment are lacking. AIM:To assess whether tegaserod retreatment is as efficacious an...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.2004.02294.x

    authors: Müller-Lissner S,Holtmann G,Rueegg P,Weidinger G,Löffler H

    更新日期:2005-01-01 00:00:00

  • Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis--a double-blind, double-dummy study.

    abstract:BACKGROUND:The herbal treatment with myrrh, dry extract of chamomile flowers and coffee charcoal has anti-inflammatory and antidiarrhoeal potential and might benefit patients with UC. Aminosalicylates are used as standard treatment for maintaining remission in ulcerative colitis (UC). AIM:To compare the efficacy of th...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/apt.12397

    authors: Langhorst J,Varnhagen I,Schneider SB,Albrecht U,Rueffer A,Stange R,Michalsen A,Dobos GJ

    更新日期:2013-09-01 00:00:00

  • The impact of hepatitis C burden: an evidence-based approach.

    abstract:BACKGROUND:Infection with the hepatitis C virus (HCV) has been considered a major cause of mortality, morbidity and resource utilisation in the US. In addition, HCV is the main cause of hepatocellular cancer (HCC) in the US. Recent developments in the diagnosis and treatment of HCV, including new recommendations pertai...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12625

    authors: Younossi ZM,Kanwal F,Saab S,Brown KA,El-Serag HB,Kim WR,Ahmed A,Kugelmas M,Gordon SC

    更新日期:2014-03-01 00:00:00

  • Review article: indications for anti-reflux surgery and endoscopic anti-reflux procedures.

    abstract::Gastro-oesophageal reflux disease is a motor disorder principally caused by defective function of the lower oesophageal sphincter. Proton pump inhibitor (PPI) drugs alleviate symptoms, heal oesophagitis and improve quality of life but do not address the underlying motor disorder, and prolonged treatment is often neede...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2004.02226.x

    authors: Palmer K

    更新日期:2004-12-01 00:00:00

  • Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients.

    abstract:BACKGROUND:Adalimumab, at an induction dose of 160/80 mg followed by 40 mg every other week is approved for treatment of refractory Crohn's disease (CD) and for patients with loss of response to infliximab. AIM:To evaluate the indications for adalimumab, the proportion of inflammatory bowel disease patients who requir...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2008.03878.x

    authors: Swaminath A,Ullman T,Rosen M,Mayer L,Lichtiger S,Abreu MT

    更新日期:2009-02-01 00:00:00

  • Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease.

    abstract:BACKGROUND:There is a need for a simple, therapeutic test that is of diagnostic value and can also provide rapid symptom relief in patients who present with classic, mild symptoms suggestive of gastro-oesophageal reflux disease (GERD), when the diagnosis is based on symptom assessment alone. AIM:To assess the diagnost...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1999.00429.x

    authors: Bate CM,Riley SA,Chapman RW,Durnin AT,Taylor MD

    更新日期:1999-01-01 00:00:00

  • An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.

    abstract::Forty-two patients with peptic ulceration of the duodenum, stomach or oesophagus, who had not responded to 3 or more months of high-dose treatment with ranitidine (450 or 600 mg/day), were treated with oral lansoprazole at 30-60 mg daily. In 40 patients (95.2%) the ulcers healed within 2-12 weeks. In the remaining 2 p...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.1993.tb00589.x

    authors: Brunner G,Arnold R,Hennig U,Fuchs W

    更新日期:1993-01-01 00:00:00

  • Oral or intravenous erythromycin has no effect on human distal colonic motility.

    abstract::Erythromycin is a prokinetic agent for the lower oesophageal sphincter, the stomach, the gallbladder and the small bowel, acting directly on motilin receptors. Its effect on pressure activity of the human colon has not been investigated. Eight healthy volunteers were studied on 2 occasions and given intravenous or ora...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1992.tb00573.x

    authors: Jameson JS,Rogers J,Misiewicz JJ,Raimundo AH,Henry MM

    更新日期:1992-10-01 00:00:00

  • Withdrawal of corticosteroids in inflammatory bowel disease patients after dependency periods ranging from 2 to 45 years: a proposed method.

    abstract:BACKGROUND:Even in the biologic era, corticosteroid dependency in IBD patients is common and causes a lot of morbidity, but methods of withdrawal are not well described. AIM:To assess the effectiveness of a corticosteroid withdrawal method. METHODS:Twelve patients (10 men, 2 women; 6 ulcerative colitis, 6 Crohn's dis...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2009.04136.x

    authors: Murphy SJ,Wang L,Anderson LA,Steinlauf A,Present DH,Mechanick JI

    更新日期:2009-11-15 00:00:00

  • Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro.

    abstract:BACKGROUND:Oral aloe vera gel is widely used by patients with inflammatory bowel disease and is under therapeutic evaluation for this condition. AIM:To assess the effects of aloe vera in vitro on the production of reactive oxygen metabolites, eicosanoids and interleukin-8, all of which may be pathogenic in inflammator...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2004.01874.x

    authors: Langmead L,Makins RJ,Rampton DS

    更新日期:2004-03-01 00:00:00

  • Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome.

    abstract:BACKGROUND:Alterations in serotonergic (5-HT) metabolism and/or intestinal integrity have been associated with irritable bowel syndrome (IBS). AIMS:To assess the effects of the precursor of 5-HT, 5-hydroxytryptophan (5-HTP), on mucosal 5-HT availability and intestinal integrity, and to assess potential differences bet...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/apt.12842

    authors: Keszthelyi D,Troost FJ,Jonkers DM,van Eijk HM,Lindsey PJ,Dekker J,Buurman WA,Masclee AA

    更新日期:2014-08-01 00:00:00

  • Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis--a double-blind, placebo-controlled study.

    abstract:BACKGROUND:Pancreatic exocrine insufficiency (PEI) results in maldigestion, leading to abdominal pain, steatorrhoea, malnutrition and weight loss. AIM:To assess the efficacy and safety of pancreatin (Creon 40000 MMS) in treating PEI due to chronic pancreatitis (CP). METHODS:This was a 1-week, double-blind, randomised...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2012.05202.x

    authors: Thorat V,Reddy N,Bhatia S,Bapaye A,Rajkumar JS,Kini DD,Kalla MM,Ramesh H

    更新日期:2012-09-01 00:00:00

  • Efficacy of continuous therapy for peptic ulcer in controlled clinical trials.

    abstract::Long-term studies have confirmed unequivocally the clinical efficacy of continuous therapy with H2-receptor antagonists in reducing the incidence of ulcer recurrence. However, studies have also reported varying relapse rates as a result of differences in study design, particularly the frequency of endoscopy and hence ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.1993.tb00595.x

    authors: Dammann HG,Walter TA

    更新日期:1993-01-01 00:00:00

  • Effect of mefenamic acid on bowel transit time in healthy adult volunteers.

    abstract::The effect of mefenamic acid on bowel transit time was investigated. Seven healthy adult male subjects of age 39 +/- 2.4 years (mean +/- S.E.M.) received placebo or mefenamic acid (500 mg t.d.s) orally in randomized order for five days, with a 7-day washout between studies. On the third morning after starting the drug...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1990.tb00488.x

    authors: Rashid MU,Bateman DN

    更新日期:1990-08-01 00:00:00

  • Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial.

    abstract:BACKGROUND:Misoprostol is known to be effective in stimulating intestinal transit both in healthy individuals and in patients with chronic constipation when evaluated in short-term trials. The aim of this study was to determine the utility of misoprostol in the long-term management of patients with chronic refractory c...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.1997.00237.x

    authors: Roarty TP,Weber F,Soykan I,McCallum RW

    更新日期:1997-12-01 00:00:00

  • The effect of bolus viscosity on swallowing function in neurogenic dysphagia.

    abstract:AIM:To assess the pathophysiology and treatment of neurogenic dysphagia. METHODS:46 patients with brain damage, 46 with neurodegenerative diseases and eight healthy volunteers were studied by videofluoroscopy while swallowing 3-20 mL liquid (20.4 mPa s), nectar (274.4 mPa s) and pudding (3931.2 mPa s) boluses. RESULT...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.03118.x

    authors: Clavé P,de Kraa M,Arreola V,Girvent M,Farré R,Palomera E,Serra-Prat M

    更新日期:2006-11-01 00:00:00

  • Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome.

    abstract:AIM:To update previous overviews of placebo-controlled double-blind trials assessing the efficacy and tolerance of smooth muscle relaxants in irritable bowel syndrome. METHODS AND TRIALS: A total of 23 randomized clinical trials were selected for meta-analyses of their efficacy and tolerance. Six drugs were analysed: c...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1046/j.1365-2036.2001.00937.x

    authors: Poynard T,Regimbeau C,Benhamou Y

    更新日期:2001-03-01 00:00:00

  • The impact of gastrointestinal symptoms on health status in patients with cardiovascular disease.

    abstract:BACKGROUND:Drugs for the management of cardiovascular disease may provoke gastrointestinal discomfort and complications. AIM:To evaluate whether upper gastrointestinal symptoms affect the health status of patients with cardiovascular disease. METHODS:Two weeks after discharge, 958 consecutive patients, who had been a...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2003.01542.x

    authors: Laheij RJ,Van Rossum LG,Krabbe PF,Jansen JB,Verheugt FW

    更新日期:2003-04-01 00:00:00

  • Efficacy of a standard United Kingdom oral rehydration solution (ORS) and a hypotonic ORS assessed by human intestinal perfusion.

    abstract::Human triple-lumen intestinal perfusion was used to compare water and solute absorption from the oral rehydration solution (ORS) most widely used in the United Kingdom and a new experimental hypotonic ORS (HYPO-ORS). HYPO-ORS (osmolality 210 mOsm/kg) promoted significantly greater water absorption than UK-ORS (7.03 +/...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1989.tb00249.x

    authors: Hunt JB,Elliott EJ,Farthing MJ

    更新日期:1989-12-01 00:00:00

  • A regional audit of iatrogenic perforation of tumours of the oesophagus and cardia.

    abstract:INTRODUCTION:With the rising incidence of oesophageal cancer, palliative treatment has an increasingly important role. With median survival unlikely to exceed 6 months, in advanced disease the palliative therapy chosen must not hasten patient's demise. AIM:To establish the outcome of both modern and historical palliat...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2005.02324.x

    authors: Jethwa P,Lala A,Powell J,McConkey CC,Gillison EW,Spychal RT

    更新日期:2005-02-15 00:00:00

  • Use of proton pump inhibitors and the risk of cholangitis: a nationwide cohort study.

    abstract:BACKGROUND:Proton pump inhibitor (PPI) use may alter the gut microbiome and increase the risk of cholangitis. However, the association of PPI use with the risk of incident cholangitis has not been evaluated. AIM:To evaluate whether PPI use was associated with a higher risk of cholangitis. METHODS:This cohort study in...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15466

    authors: Min YW,Kang D,Shin JY,Kang M,Park JK,Lee KH,Lee JK,Lee KT,Rhee PL,Kim JJ,Guallar E,Cho J,Lee H

    更新日期:2019-10-01 00:00:00

  • Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough.

    abstract:BACKGROUND:Twice-daily dosing is increasingly used to improve gastric acid control, although not all proton-pump inhibitors are more effective when doses are split. Standard dose esomeprazole provides better gastric acid control than other standard dose proton-pump inhibitors. AIMS:To compare the effect of standard do...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2004.01949.x

    authors: Hammer J,Schmidt B

    更新日期:2004-05-15 00:00:00

  • Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome.

    abstract:BACKGROUND:Studies assessing the prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome gave contrasting results. Differences in criteria to define irritable bowel syndrome patients and methods to assess small intestinal bacterial overgrowth may explain different results. Moreover, no data exis...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2005.02690.x

    authors: Lupascu A,Gabrielli M,Lauritano EC,Scarpellini E,Santoliquido A,Cammarota G,Flore R,Tondi P,Pola P,Gasbarrini G,Gasbarrini A

    更新日期:2005-12-01 00:00:00

  • Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data.

    abstract:BACKGROUND:Limited therapeutic options exist for severe gastroparesis, where severe nausea and vomiting can lead to weight loss, dehydration and malnutrition due to inadequate caloric and fluid intake. TZP-101 (ulimorelin) is a ghrelin receptor agonist that accelerates gastric emptying and improves upper gastrointestin...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2010.04567.x

    authors: Wo JM,Ejskjaer N,Hellström PM,Malik RA,Pezzullo JC,Shaughnessy L,Charlton P,Kosutic G,McCallum RW

    更新日期:2011-03-01 00:00:00

  • A controlled trial of ondansetron in the pruritus of cholestasis.

    abstract:BACKGROUND:In patients with pruritus of cholestasis, response to conventional drug treatment may be unsatisfactory. Activation of 5-hydroxytryptamine receptors on dermal sensory nerve-endings plays a role in the perception of pruritus. The 5-hydroxytryptamine(3) receptor antagonist, ondansetron, has been used in the tr...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2005.02430.x

    authors: O'Donohue JW,Pereira SP,Ashdown AC,Haigh CG,Wilkinson JR,Williams R

    更新日期:2005-04-15 00:00:00

  • Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study.

    abstract:BACKGROUND:Data on tenofovir alafenamide fumarate (TAF) for preventing mother-to-child transmission of hepatitis B virus (HBV) are lacking. AIMS:To investigate the efficacy and safety of TAF therapy for preventing hepatitis B mother-to-child transmission. METHODS:Mothers with chronic HBV infection, positive for hepat...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.16043

    authors: Ding Y,Cao L,Zhu L,Huang Y,Lin C,Wang Y,Liu Y,Sheng Q,Wang S,Fan J,Chen R,Gan W,Chen B,Pan CQ

    更新日期:2020-10-01 00:00:00